S-100A4 protein and mesothelin expression in dysplasia and carcinoma of the extrahepatic bile duct

American Journal of Clinical Pathology

Volumn 127, Issue 3, 2007, Pages 374-379

  Zhao, Huicong ^a   Davydova, Larisa ^a   Mandich, Daniza ^a   Cartun, Richard W ^a   Ligato, Saveno ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Extrahepatic biliary dysplasia and malignancy; Immunohistochemistry; Mesothelin; S 100A4 protein

Indexed keywords

CALVASCULIN; MESOTHELIN; MEGAKARYOCYTE POTENTIATING FACTOR; MEMBRANE PROTEIN; PROTEIN S 100; S100A4 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ARTICLE; BILE DUCT CARCINOMA; CANCER GRADING; CANCER INVASION; CARCINOMA IN SITU; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE SECTION; TUMOR DIFFERENTIATION; ADENOCARCINOMA; BILE DUCT TUMOR; BIOSYNTHESIS; CHEMISTRY; EPITHELIUM; HEPATIC DUCT; METABOLISM; PATHOLOGY;

ADENOCARCINOMA; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; CARCINOMA IN SITU; EPITHELIUM; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE GLYCOPROTEINS; NEOPLASM INVASIVENESS; S100 PROTEINS;

EID: 34247860743     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/37RTWYAEPABYY410     Document Type: Article

References (23)

1. Albores-Saavedra J, Henson DE, Klimstra DS. Tumors of the Gallbladder, Extrahepatic Bile Ducts, and Ampulla of Vater. Washington, DC: Armed Forced Institute of Pathology; 2000. Atlas of Tumor Pathobgy; Third series, Fascicle 27.
2. Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the extrahepatic bile ducts: histologic types, stage of disease, grade, and survival rates. Cancer. 1992;70:1498-1501.
3. Curley S. Biliary tract cancer. Cancer Treat Res. 1997;90:273-307.
4. Henke AC, Jensen CS, Cohen MC. Cytologic diagnosis of adenocarcinoma in biliary and pancreatic duct brushings. Adv Anat Pathol. 2002;9:301-308.
5. Schafer BW, Heizmann CW. The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci. 1996;21:134-140.
6. Mazzucchelli L. Protein 100A4: too long overlooked by pathologists? Am J Pathol. 2002;160:7-13.
7. Takenaga K, Nakanishi H, Wada K, et al. Increased expression of S100A4, a metastasis-associated gene, in human colorectal adenocarcinoma. Clin Cancer Res. 1997;3:2309-2316.
8. Albertazzi E, Cajone F, Leone B, et al. Metastasis-associated genes h-mts1 (S100A4) and nm23 in carcinoma of breast is related to disease progression. DNA Cell Biol. 1998;17:335-342.
9. Ninimiya L, Ohta T, Fushida S, et al. Increased expression of S100A4 and its prognostic significance in esophageal squamous cell carcinoma. Int J Oncol. 2001;18:715-720.
10. Yonemura Y, Endou Y, Kimura K, et al. Inverse expression of S100A4 and E-cadherin is associated with metastatic potential in gastric cancer. Clin Cancer Res. 2000;6:4234-4242.
11. Nakamura T, Ajiki T, Murao S, et al. Prognostic significance of S100A4 expression in gallbladder cancer. Int J Oncol. 2002;20:937-941.
12. Kimura K, Endo Y, Yonemura Y, et al. Clinical significance of S100A4 and E-cadherin-related adhesion molecules in non-small cell lung cancer. Int J Oncol. 2000;16:1125-1131.
13. Katayama N, Murao S, Ajiki T, et al. The role of S100A4 gene encoding an S100-related calcium-binding protein in human bile duct adenocarcinoma cell lines: correlation of S100A4 expression and invasive growth in Matrigel Matrix. Int J Mol Med. 2000;6:539-542.
14. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A. 1996;93:136-140.
15. Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody reactive with ovarian cancer and normal mesothelium. Int J Cancer. 1992;50:373-381.
16. Chang K, Pai LH, Pass H, et al. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol. 1992;16:259-268.
17. Chang K, Pastan I, Willingham M. Frequent expression of the tumor antigen CAK1 in squamous-cell carcinoma. Int J Cancer. 1992;51:548-554.
18. Hassan R, Laszik Z, Lerner M, et al. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol. 2005;124:838-845.
19. Swierczynski SL, Maitra A, Abraham SC, et al. Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol. 2004;35:357-366.
20. Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001;7:3862-3868.
21. Ordoñez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003;27:1418-1428.
22. Tascilar M, Offerhaus JA, Altink R, at al. Immunohistochemical labeling for the Dpc4 gene product is a specific marker for adenocarcinoma in biopsy specimens of the pancreas and bile duct. Am J Clin Pathol. 2001;116:831-837.
23. Argani P, Shaukat A, Kaushal M, et al. Differing rates of loss of Dpc4 expression and of p53 overexpression among carcinoma of the proximal and distal bile ducts: evidence for biological distinction. Cancer. 2001;91:1332-1341.